Head and neck squamous cell carcinomas responded better to a combination of two immunotherapies than to one immunotherapy ...

Guttman-Yassky received research support, consulting, or lecture fees on atopic dermatitis from Regeneron, Sanofi, Pfizer, ...

Mestag Therapeutics, a leading biotech company specialising in fibroblast immunology for inflammatory disease and cancer, has ...

Kiniksa is shifting to next-gen IL-1 antibodies for recurrent pericarditis. Click here to read more on how this impacts KNSA stock in 2025 and beyond.

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.

Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively –– ARCALYST 2025 net product revenue expected to be $560 - $580 million –– KPL-387 Phase 2/3 clinical ...

Earlier in his career, whilst Dr. Sleeman was the Cambridge site lead for the Respiratory, Inflammation and Autoimmunity ...

Cambridge biotech company Mestag Therapeutics has appointed experienced executive Dr Matthew Sleeman as Chief Scientific Officer. Mestag is harnessing fibroblast immunology for patients with ...

Mestag Therapeutics ("Mestag"), a biotech company harnessing fibroblast immunology for the benefit of patients with inflammatory disease and ...

MedImmune will explore the target, linker, warhead selection: Do's and Don’ts; five rights of creation of the best optimized fit-for-purpose ADCs; internalisation of ADCs – how to improve ...

The biotech licensed the asset from AstraZeneca’s MedImmune in 2017, paying $23 million in upfront and subsequent payments. But by early last year, the company was evaluating potential ...